Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215644
Status:
COMPLETED
Last Update Posted:
2018-11-02
First Post:
2005-09-15
Brief Title:
Matuzumab Treatment With Epirubicin Cisplatin and Capecitabine ECX in Esophago-Gastric Cancer
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
Randomized Phase II Open-Label Controlled Study of EMD 72000 Matuzumab in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MATRIX EG
Brief Summary:
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy with ECX chemotherapy Participants invited to take part have metastatic cancer of the esophagus gullet or stomach
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-000146-36 | EUDRACT_NUMBER | None | None |